Document is current
Any future updates will be listed below
-
Authors
Rades, Dirk
Bartscht, Tobias
Hunold, Peter
Schmidberger, Heinz
König, Laila
Debus, Jürgen
Belka, Claus
Homann, Nils
Spillner, Patrick
Petersen, Cordula
Kuhnt, Thomas
Fietkau, Rainer
Ridwelski, Karsten
Karcher-Kilian, Kerstin
Kranich, Anne
Männikkö, Sofia
Schild, Steven E.
Maderer, Annett
Moehler, Markus
-
Funding
Funding for this research was provided by:
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
- License Information
-
More Information
Article History
Received: 9 April 2020
Accepted: 23 May 2020
First Online: 12 June 2020
Compliance with ethical guidelines
:
: D. Rades received speakers’ honoraria and travel grants from Merck Serono, Roche Pharma, Bristol Myers Squibb, Astra Zeneca, and Amgen until 2015. S.E. Schild edits and writes for UpToDate and has done consulting work for Noxopharm in the past. T. Bartscht, P. Hunold, H. Schmidberger, L. König, J. Debus, C. Belka, N. Homann, P. Spillner, C. Petersen, T. Kuhnt, R. Fietkau, K. Ridwelski, K. Karcher-Kilian, A. Kranich, S. Männikkö, A. Maderer, and M. Moehler declare that they have no competing interests.
: The study has been approved by the ethics committee of the University of Lübeck (reference: 11-104). The study was conducted in accordance with the principles laid out in the Declaration of Helsinki and in accordance with the principles of Good Clinical Practice. Informed consent was obtained from all individual participants included in the study.
